Advanced Medical Solutions ((GB:AMS)) announced an update on their ongoing clinical study.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Study Overview: Advanced Medical Solutions is conducting a Post Market Surveillance Study titled ‘Post Market Surveillance Study to Confirm the Ongoing Safety and Performance of Silver II Non-woven Dressing in Chronic and Acute Wounds.’ The study aims to validate the safety and effectiveness of the Silver II Non-woven Dressing in treating chronic and acute wounds, emphasizing its significance in wound care management.
Intervention/Treatment: The study focuses on the Silver II Non-woven Dressing, a medical device designed to treat chronic and acute wounds. This dressing is intended to ensure effective wound management and promote healing.
Study Design: The study is interventional with a single-group model and no masking. Its primary purpose is treatment, assessing the dressing’s impact on wound healing without a control group for comparison.
Study Timeline: The study began on September 7, 2021, and is currently recruiting participants. The latest update was submitted on January 27, 2025, indicating ongoing progress and commitment to comprehensive data collection.
Market Implications: The successful validation of the Silver II Non-woven Dressing could positively influence Advanced Medical Solutions’ stock performance by enhancing investor confidence in its product offerings. This development might also impact the competitive landscape in the wound care industry, prompting attention from investors and competitors alike.
The study is ongoing, with further details available on the ClinicalTrials portal.